Evidence map›Paper›PMID 32592131›Full record

Trial reportLasers in medical science2021

The efficacy of a single-session pro-yellow laser in the treatment of facial telangiectasia.

Dursun Turkmen, Nihal Altunisik, Serpil Sener

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Lasers in medical science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
1.2field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 13 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Dursun TurkmenFaculty of Medicine, Department of Dermatology, Inonu University, Malatya, Turkey. dursunturkmen44@gmail.com.ORCID https://orcid.org/0000-0001-9076-4669
Nihal AltunisikFaculty of Medicine, Department of Dermatology, Inonu University, Malatya, Turkey.ORCID https://orcid.org/0000-0001-6844-1097
Serpil SenerFaculty of Medicine, Department of Dermatology, Inonu University, Malatya, Turkey.ORCID https://orcid.org/0000-0002-7012-2666
Inonu University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Facial telangiectasia (FT) is a condition in which small dilated vessels visibly protrude on the surface of the skin. The aim of this study was to evaluate the efficacy and safety of a single-session pro-yellow laser in the treatment of FT and spider angioma (SA) to compare it with a limited number of studies conducted on this subject. In this pilot study, we reviewed 41 patients who admitted to our dermatology clinic with FT and SA and were treated by using pro-yellow laser. The efficacy of the treatment was evaluated using the recorded clinical information and digital camera images. The improvement was graded as complete (90-100%), very good (75-89%), good (50-74%), moderate (25-49%), and weak (< 25%). Of the 41 patients included in the study, 37 (90.2%) had FT and four (9.8%) had SA. Twenty-two patients were female and 19 were male. Pro-yellow laser therapy was generally well tolerated by patients, and minimal pain occurred during the application. In 1-month follow-up, good, very good, or complete recovery was achieved in 51.4% of the FT patients. The new pro-yellow laser only has a yellow light wavelength. Its unique wavelength at 577-nm yellow light is ideal for vascular lesions. In this study, 51.4% of the patients with FT achieved good, very good, or complete improvement after a single session of 577-nm pro-yellow laser, and complete improvement was achieved in all the four patients with SA.

Indexed as

Laser TherapyAdolescentAdultAgedChildFaceFemaleHumansMaleMiddle AgedPilot ProjectsTelangiectasisTreatment OutcomeYoung Adult577 nmFacial telangiectasia,Laser therapy,Pro-yellow laser,Spider angioma,

Identifiers

PMID32592131
OpenAlexW3038002784

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.